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 Definition                           
 Exosomes are involved in intracellular 
communication
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Exosome
Highly specialized 
double membrane 
structures
 Tumor cells have various mechanisms against 
immune system
Such as secretion of exosomes
TEX: Tumor-derived Exosomes 
Exosomes can be carriers of various proteins, lipids, miRNAs 
and m RNAs                                  
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 The role of exosomes
influence in metastasis and cancer progression
involve in multidrug resistance mechanisms
Enables cancer cells to evade from recognition by 
host immune cells
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 The role of exosomes
role as communication vehicles between cells
Responsible for the formation of vessels
Prognosis of cancer
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 Exosome: source of information concerning 
prognosis
Patient condition and the effectiveness of applied 
treatment
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 Source of exosome
Exosome can be obtained 
from: 
 Amniotic fluids
 ascites
 nasal lavage fluid 
 Serum 
 Plasma 
 Milk
 Urine
 CSF
 Cell culture medium
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 Factors affecting the content and amount of vesicles:
 Physical factors: ionizing radiation, heat
 Chemical factors: low pH level, increased concentration of calcium, 
oxidative stress, hypoxia
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The Origin of Exosomes
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 The type and biogenesis of different extracellular vesicles
14The role of exosomes in tumor progression and metastasis (Review)
 ILV:
Intra Luminal Vesicles
 MVB:
Multi Vesicular Body 
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 MVB: an intracellular  compartment containing multiple vesicles 
with the plasma membrane.
MVBs are assembled from vesicles sorted from the trans- Golgi network 
or from internalized membrane
16The role of exosomes in tumor progression and metastasis (Review)
 MVB pathways variants:
MVB can fuse with lysosomes for protein degradation 
Or release their ILV by fusing with the plasma membrane.
The release vesicles are termed exosomes
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18The role of exosomes in tumor progression and metastasis (Review)
ESCRT: endosomal sorting complex required for transport
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Endosome ESCRT
Sorts 
ubiquitinylated 
proteins into ILV 
of MVB
Degraded 
when MBV 
fuse with 
lysosomes
Exocytose 
(Exosome) 
 ESCRT complex
 The sub complex  of  ESCRT complex 
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ESCRT I
ESCRT II
ESCRT III
Tsg 101 ( tumor 
susceptibility gene) 
in the ESCRT
complex I
binds ubiquitinated
proteins
Recruits 
ESCRT II
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ESCRT II ESCRT III
ESCRT III
recruits a deubiquitinating enzyme
that removes the ubiquitin tag from 
the cargo proteins prior to sorting 
into MVB
22Cancer Gene Pro ling / chapter 7
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APC
(antigen 
presenting 
cells)
release exosomes derived from the
Major histocompatibility (MHC)
class II compartment, a subset of
MVB.
Exosome 
containing 
RNA or 
miRNA
induce exogenous gene expression 
and mediate gene silencing
Exosome Characterization
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 Exosome constituents: Exosomes are composed of a lipid bilayer
enriched in cholesterol, sphingomyelin,GM3, and phosphatidylserine.
 Exosomes are 50–100 nm in size and, according to the lipid
composition, have a density of 1.14–1.17 g/l
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Constitutive membrane components 
are tetraspanins, adhesion molecules, 
proteases, and trans membrane 
receptors
Exosome Isolation
26
 Exosomes being released in the extracellular space are purified from 
cell culture supernatants and biological fluids 
 Commonly used isolation methods:
ultracentrifugation at 100,000 × g for 1–2 h to pellet the Exosomes Size 
chromatography preferably HPLC
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Exosome and Cancer
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 Role of  TEX in immune suppression
29
they carry immunosuppressive molecules
and factors known to interfere with immune 
cell functions
TEX also deliver genomic DNA, mRNA, and
microRNAs to immune cells, thereby
reprogramming functions of responder cells to
promote tumor progression. TEX carrying
tumor-associated antigens can interfere with
antitumor immunotherapies.
• TEX carry inhibitory ligands that bind to cognate receptors on 
immune cells, inducing negative signaling .
• The two key receptors on immune cells, the T cell receptor (TCR) and 
the IL-2 receptor (IL-2R), are negatively regulated by TEX.
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 The effect on T lymphocyte
inhibition of CD3ζ chain expression and reduced levels of mRNA coding
for the CD3ζ chain
( CD 3 T lymphocytes phenotypic marker)
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 The effect on T lymphocyte
TEX reduce JAK kinase expression in activated T cells .The integrity of 
the JAK pathway is critical for the functions of cytokines sharing the γ-
chain of the IL-2R (IL-2, IL-7, IL-15);
thus, suppression of IL-2R γ-chain phosphorylation levels leads to the 
failure of T cells to produce these cytokines and to proliferate
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 The effect on T CD𝟖+
Experiments showed that TEX inhibited the proliferation of human 
CD8+ T cells
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 TEX induce apoptosis of activated CD8+ T effector  
Nearly all CD8+ T lymphocytes in the circulation of cancer patients 
express surface CD95 (Fas receptor), and many express programmed 
death 1 (PD-1)
Therefore, they are susceptible to apoptosis by TEX carrying the 
membrane form of FasL or programmed death ligand 1 (PD-L1), 
respectively. 
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 The effect on NK cell
TEX suppress NK cell activity. The frequency and activity of NK
cells are often depressed in cancer patients compared with age-
matched, healthy individuals.
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 The effect on NK cell
Additionally, expression levels of the NK cell–activating receptors
NKp30, NKp46, NKG2C, and NKG2D are low in cancer patients .
TEX downregulate expression of NKG2D and reduce NK cell
cytotoxicity
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 The effect on monocyte 
TEX interfere with monocyte differentiation. Co incubation of peripheral
blood monocytes (PBMCs) with TEX promoted their differentiation into 
TGF-β–expressing DCs,
which also secreted PGE2 and interfered with cytotoxic T lymphocyte 
(CTL) generation.
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 The effect on monocyte 
DCs generated in the presence of TEX expressed low levels of
costimulatory molecules and induced dose-dependent inhibition
of T cell proliferation.
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 The effect on myeloid precursor 
TEX skew the differentiation of myeloid precursor cells into 
(myeloid – derived suppressor cells) 
MDSC accumulation has a two-fold effect on the immune response: first, 
with the paucity or absence of DCs, antigen processing and presentation 
are negatively affected,
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MDSCs
 The effect on myeloid precursor 
and, second, the newly minted MDSCs produce numerous
immunosuppressive inhibitory factors, including NO and ROS,
which cause nitration of TCRs or T cell apoptosis
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 The effect on T regulator 
TEX drive differentiation and expansion of Tregs. The frequency of
circulating CD𝟒+CD𝟐𝟓+FOXP𝟑+ Tregs is often elevated in patients with
cancer
TEX induced the conversion of human conventional CD𝟒+CD𝟐𝟓− T
cells to CD𝟒+CD𝟐𝟓+FOXP𝟑+Tregs
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42Exosomes and tumor-mediated immune suppression (Review) 
 As TEX are known to carry TAAs ( Tumor Associated Antigens), they
can efficiently bind and sequester tumor-reactive Abs and
dramatically reduce binding of these Abs to tumor cells.
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Exosome as a diagnostic tool
45
 They are released by the majority of the cells and contain detailed
molecular information of the tumor cells
 Exosomes can be isolated from easy accessible body fluids, and most
importantly, they can provide several biomarkers, with different
levels of specificity
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 Recent clinical evidence shows that the levels of Exosomes released
into body fluids may themselves represent a predictive/diagnostic of
tumors
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exosome as therapeutics
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 They are small and flexible, which allows them
to cross biological membranes.
 By a lipid bilayer they protect their cargo from degradation.
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 The capacity of exosomes to serve as bio vesicles for nucleic acids,
proteins, and lipids, and their role in intercellular communication,
make them a versatile platform for drug delivery
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 Exosomes are intrinsically bioactive; thus, they can be isolated from
cells for downstream use without further modification
 modification of exosomes allowing researchers to specifically
customize or tailor exosomes to particular applications
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 Exosome as therapeutic in Alzheimer’s disease
Alvarez-Erviti and colleagues were the first to enrich exosomes with
siRNAs and genetically equip them with neuron-specific rabies virus
glycoprotein (RVG) peptides to target the brain
They were able to silence 60% of beta-secretase 1 (BACE-1) expression, a
key player in the progression of Alzheimer’s disease
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 Since then, a variety of studies have reported the use of exosomes for
the treatment in various diseases including in :
oncology, neurology, ischemic diseases, liver disease, therapeutic
vaccination, and immune disorders
54
Conclusion
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 TEX are rapidly emerging as a critical component of a tumor
orchestrated information system that is designed to facilitate
tumor immune escape and promote tumor growth
 Unique exosomal cargo contents can be used in the future as potential
predictive biomarkers, which enable the observation of patients
before and during treatment
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 However, the specific separation of only one extracellular membrane
vesicle subpopulation is problematic
due to the wide size range, and characterization of their content remains
a challenge for researchers.
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